Patent application number | Description | Published |
20090063123 | SYSTEMS, METHODS AND COMPUTER PRODUCTS FOR DATABASE CLUSTER MODELING - Generating in a computer system and deploying a data model of a plurality of database cluster configuration availability solutions over a computer network by creating a database cluster configuration modeling specification including objects contained in a unified model language diagram providing a definition of a database cluster configuration data model. Creating the database cluster configuration data model using the database cluster configuration modeling specification and upon receiving signals from a graphical user interface or from XML batch data files or from application programming interfaces, indicating the definition of the cluster configuration model. After creating the graphical database cluster configuration data model, constraints that specify a valid logical configuration are validated and the solution is transformed into data understandable by database cluster manager software applications and then transmitted over a network to multiple cluster manager targets to be incorporated as database cluster configuration availability solutions. | 03-05-2009 |
20090063501 | SYSTEMS, METHODS AND COMPUTER PRODUCTS FOR GENERATING POLICY BASED FAIL OVER CONFIGURATION FOR DARABASE CLUSTERS - Generating a plurality of database cluster failover policy availability configuration modeling solutions by a database cluster management system in an environment of networked computer systems includes receiving a first signal from a user system specifying one of a plurality of database cluster failover policy type behavior patterns. The database cluster management system determines whether generating any of the failover policy type behavior patterns requires additional supplemental data. If no supplemental data are required, then the database cluster management system generates general database cluster policy solutions. If supplemental data are required, then the system utilizes an algorithm to generate unique, specific policy solutions by creating failover node sequences for each of the plurality of failover policy type behavior patterns requiring such additional supplemental data. The entire solutions can be displayed and then transmitted to multiple database cluster managers over a network to correct availability failure in networked database cluster configurations. | 03-05-2009 |
20110145627 | IMPROVING DATA AVAILABILITY DURING FAILURE DETECTION AND RECOVERY PROCESSING IN A SHARED RESOURCE SYSTEM - A system and method for managing shared resources is disclosed. The system includes a primary coherency processing unit which processes lock requests from a plurality of data processing hosts, the primary coherency processing unit also storing a first current lock state information for the plurality of data processing hosts, the first current lock state information including a plurality of locks held by the plurality of data processing hosts. The system further includes a standby coherency processing unit storing fewer locks than the primary coherency processing unit, the locks stored by the standby coherency processing unit being a subset of locks included in the first current lock state information, the standby coherency unit configured to perform a plurality of activities of the primary coherency processing unit using the subset of locks in response to a failure of the primary coherency processing unit. | 06-16-2011 |
Patent application number | Description | Published |
20090311245 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 12-17-2009 |
20100056761 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 03-04-2010 |
20100266584 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 10-21-2010 |
20110123523 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 05-26-2011 |
20120027774 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 02-02-2012 |
20120244163 | BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF - Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways. | 09-27-2012 |
20130108650 | ACTRIIB BINDING AGENTS AND USES THEREOF | 05-02-2013 |
20130189269 | ACTRIIB BINDING AGENTS AND USES THEREOF - The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same. | 07-25-2013 |
20140234329 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 08-21-2014 |
20150030606 | ACTRIIB BINDING AGENTS AND USES THEREOF - The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same. | 01-29-2015 |
Patent application number | Description | Published |
20110195454 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments. | 08-11-2011 |
20120021409 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided. | 01-26-2012 |
20120192300 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided. | 07-26-2012 |
20130045492 | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided. | 02-21-2013 |
20130185821 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided. | 07-18-2013 |
20130198879 | Humanized Universal Light Chain Mice - Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express humanized heavy chains comprising human variable domains, and that express humanized light chains comprising human variable domains wherein the light chains are derived from no more than one, or no more than two, light chain V and J or rearranged V/J sequences. Fertile male mice that express antibodies with universal light chains and humanized heavy chains are provided. Methods and compositions for making bispecific binding proteins are provided. | 08-01-2013 |
20130198880 | MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. | 08-01-2013 |
20130302836 | COMMON LIGHT CHAIN MOUSE - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments. | 11-14-2013 |
20150313193 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided. | 11-05-2015 |